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Table. Results and indications for percutaneous endovascular aortic aneurysm repair (PEVAR) utilizing superﬁcial femoral artery (SFA)
Patient MAIN LIMB Indication for SFA Complication
Follow-up CT
results
Time to
follow-up
(months)
Device
caliber
R (F)
Device
caliber
L (F)
1 R SFA L SFA Calciﬁed bilateral CFAs, morbid obesity None Patent R & L SFA 1 18 14
2 R SFA Calciﬁed bilateral CFAs None Patent R SFA 2 18
3 R SFA Morbid obesity, prior groin infections None Patent R SFA 1 16
4 L SFA High CPA bifurcation None Patent L SFA 8 14
5 L SFA Morbid obesity Suture
Positioning bleed
Patent L SFA 8 20
6 L SFA R SFA Morbid obesity SFA thrombus Patent R & L SFA 8 14 20
7 L SFA R SFA Tortuous iliac arteries None Patent R & L SFA 1 16 18
8 R SFA Signiﬁcant anterior wall thrombus of R CFA None Patent R SFA 12 14
9 R SFA Calciﬁed R CFA None Patent R SFA 13 14
10 L SFA Scarring/visible repair site of L CFA None Patent L SFA 12 18
CFA, Common femoral artery.
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the Magellan Robotic Endovascular Catheter
Mirnal Chaudhary, MD, Jayne Miely, BS, John Matsuura, MD. Wright
State University, Dayton, Ohio
Objectives: The Magellan Robot catheter (Hansen Medical, Moun-
tain View, Calif) recently received clearance by the Food and Drug Admin-
istration for use on peripheral vessels. Our institution acquired the system in
January 2014. We report our institution’s initial experience with the Magel-
lan system.
Methods: We retrospectively reviewed the records for all patients
who underwent Magellan-assisted endovascular procedures between
January 28, 2014, and April 26, 2014. Prior to the ﬁrst procedure, the
attending surgeon and staff underwent simulator and model training
and certiﬁcation for the Magellan system. Patient demographics, comor-
bidities, and operative statistics were recorded for analysis in accordance
with IRB guidelines.
Results: A total of 14 patients (64% male) underwent 15 Magel-
lan-assisted therapies. The average age of our patients was 68 years.
Four patients had undergone previous open or endovascular procedures
on the treated extremity. Eight procedures involved atherosclerotic
occlusive disease of the legs, 3 aortic aneurysm repairs, 2 visceral steno-
ses, 1 subclavian artery occlusion, and 1 right innominate vein occlu-
sion. One case was aborted due to small iliac and femoral artery
access. Two cases were unsuccessful due to failure to cross a venous
chronic total occlusion and inability to advance the robotic sheath
into the innominate artery. Operative statistics included an average
blood loss of 125 6 114 mL, 57 6 42 mL contrast use, and 30 6
14 minutes of ﬂuoroscopy time, with an average radiation exposure
of 4866 6 6639 mGy.
Conclusions: The overall success rate for the Magellan system was
87%. There was a deﬁnite learning curve, as evidenced by our longer ﬂuo-
roscopy times. However, the ﬂexibility of the leader catheter and ability
to turn 180o made it possible to treat visceral arteries from the groin. We
also found an advantage with the robotic catheter in crossing the iliac bifur-
cation even in patients with acute angulation or prior stenting. As more cen-
ters acquire the Magellan system, we feel participation in the ROVER
robotic catheter registry will play a vital role in better deﬁning the proper
use of this new technology.
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Access Site Complications Are Commonly Found on Femoral Artery
Duplex Ultrasound and Associated With Age and Manual Pressure
Loren L. Masterson, MD, Todd Corby Mounir Haurani, MD, Lianbo
Yu, PhD, Jean Starr, MD. Vascular Diseases and Surgery, The Ohio State
University, Columbus, Ohio
Objectives: A duplex ultrasound study (DUS) is often the ﬁrst test to
evaluate the femoral vessels for complication after percutaneous femoral ac-
cess performed for cardiac and peripheral vascular (PV) diagnostic and inter-
ventional procedures. This retrospective study examined all patients over a
2-year period who underwent a DUS for a suspected access site complica-
tion after femoral access at our institution to try to deﬁne risk factors for
developing a complication.
Methods: The hospital peripheral vascular laboratory database was
reviewed, and all patients who underwent femoral DUS from January2010 to December 2011 were identiﬁed. Patients were excluded if they
did not have a femoral access procedure performed at our institution for
vascular or cardiac diagnostic/interventional purposes #1 month prior to
the DUS. Hospital records were reviewed, and demographics, procedural
details, and complications were recorded. Completion angiograms were
graded by a single investigator for location of puncture, femoral disease,
and size of the femoral artery.
Results: A total of 18,167 cardiac and PV procedures were performed
during the study period. A total of 222 patients had a DUS and were
divided into those with an access site complication (group A, 103 patients
[46.4%]) and those without (group B, 119 patients [53.6%]). Gender and
body mass index were similar between the groups; however, the group A
patients were signiﬁcantly older than the group B patients (62.4 vs 56.9
years; P ¼ .003). The most common complications identiﬁed on DUS
were hematoma (n ¼ 55 [53.4%]) and pseudoaneurysm (n ¼ 33
[32.0%]). A closure device was more commonly used in group B patients
(71 vs 49 patients; P ¼ .007). No single femoral anatomic feature on
completion angiogram was more commonly associated with sustaining a
complication.
Conclusions: DUS, performed for evaluation of the femoral access
site after cardiac or PV procedures, has a high yield for complications. He-
matoma is the most common complication, followed by pseudoaneurysm.
Older age and manual pressure for closure were associated with access site
complication.
Author Disclosures: L. L. Masterson: None; T. Corby: None; M.
Haurani: None; L. Yu: None; J. Starr: None.
Stent Fractures and Restenosis Rates Following Carotid Artery
Stenting
Mohammad Sarhan, MD, Sherry L. Cavanagh, MD, Robert G.
Molnar, MD. Vascular Surgery, Michigan Vascular Center/Michigan
State University/McLaren Region Medical Center, Flint, Mich
Objectives: Carotid artery stenting (CAS) is being performed more
frequently for carotid occlusive disease and has been approved for use in
high-risk patients. There have been reports of carotid stent fractures, but
prospective data are limited. To better understand the incidence of CAS
fracture and risk of restenosis, we prospectively evaluated CAS patients for
fracture and restenosis.
Methods: Patients who underwent CAS between January 2002 and
January 2012 were prospectively evaluated for stent fractures by anteropos-
terior and lateral cervical x-ray imaging and for restenosis by duplex ultra-
sound imaging at 1 month, 6 months, and 1 year. The x-ray images were
independently reviewed by two surgeons and two radiologists for the ﬁrst
part of the study and by three independent surgeons in the later part to
assess for stent fractures. The fracture incidence was then calculated as a per-
centage of the study population. Carotid duplex results were correlated to
those with and without stent fractures.
Results: During the study period, 400 stents were placed. A total of
143 patients, with 163 stents, agreed to participate in the study. Fractures
were found in 11 of the 163 stents (6%). Fractures were only counted if
there was unanimous agreement by the reviewers, and possible fractures
were not considered. Of the 11 with stent fractures identiﬁed, one patient
(9%) had a restenosis of 50% to 60% at 6 months and 1 year. Restenosis
occurred in eight of 152 (5%) without stent fractures, two of them were se-
vere (>80%) and the remaining six were <50%.
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associated with an increased risk of restenosis. The true incidence of stent
fracture may be underestimated by x-ray analysis due to limited resolution
and frequent artifacts. Additional methods to evaluate for subtle CAS frac-
tures may assist in deﬁning a more precise incidence and might lead to
insight into the potential etiologies. Further evaluation with a larger study
population and a longer follow-up both for stent integrity and its association
with restenosis or adverse clinical outcomes is needed.
Author Disclosures: M. Sarhan: None; S. L. Cavanagh: None; R. G.
Molnar: None.
Inferior Vena Cava Stenting: Technical Considerations, Early
Outcomes, and Long-Term Durability
Javairiah Fatima, MD, AbdulAziz AbdulAziz, Daniel G. Clair, MD.
Cleveland Clinic, Cleveland, Ohio
Objectives: Inferior vena cava (IVC) thrombosis is an uncommon
condition but can cause devastating complications to those affected. Histor-
ically, this has been treated with an open surgical approach, with high
morbidity, and with angioplasty in more recent years. We describe technical
aspects of IVC stenting in patients with recalcitrant chronic occlusive disease
and evaluate its outcomes.
Methods: We reviewed all of the patients treated in an endovascular
fashion for venous pathology at our institution from 2005 to 2014 to iden-
tify and include those with IVC stent placement. Clinical characteristics,
treatment details, and outcomes data were collected using medical records.
Primary end points were technical success, symptom resolution, freedom
from reintervention, and patency rate at follow-up.
Results: Twenty-eight patients (15 males), with mean age of 48 6 14
years, underwent IVC stent placement for 16 occlusions (four congenital)
and 12 high-grade stenoses. Hypercoagulable state was noted in 14 pa-
tients, seven of whom had malignancy. A previously placed IVC ﬁlter was
present in 13 patients. Median time from onset of symptoms to
presentation was 81 months (range, 3-480 months). Lytic therapy with alte-
plase was performed in 12 patients for a mean of 2 6 1 days. Self-expanding
stents (Wallstent) were used in the IVC in 22 patients, with adjunctive use
of balloon-expandable (Palmaz) stents in seven patients. Technical success
was 100%. At a median follow-up of 10 months (range, 0-56 months),
thrombotic complications requiring reintervention occurred in four patients
at 1, 4, 8, and 37 months. One patient died at 2 weeks secondary to under-
lying malignancy. Freedom from reintervention, patency rate, and symp-
tom-free survival rate at 2 years were 84%, 90%, and 80%.
Conclusions: Endovascular stenting for chronic occlusive disease of
the IVC is safe, effective, and durable, with minimal morbidity. The reinter-
vention rate is low, with excellent outcomes.
Author Disclosures: J. Fatima: None; A. AbdulAziz: None; D. G. Clair:
None.
Optimal Management of Renal Artery Aneurysms: Observation Versus
Intervention
Young Erben, Audra Duncan, MD, Adnan Rizvi, MD, Haraldur
Bjarnason, MD, Manju Kalra, MD, Gustavo Oderich, MD, Mark
Fleming, MD, Randall De Martino, MD, Thomas Bower, MD, Peter
Gloviczki, MD. Division of Vascular and Endovascular Surgery, Mayo
Clinic, Rochester, Minn
Objectives: This study evaluated outcomes of treated renal artery an-
eurysms (RAAs) and the natural history of observed RAAs.
Methods: A total of 114 patients with RAA managed from 1994 to
2014 were retrospectively reviewed. Primary outcomes included morbidity
and mortality of RAAs treated operatively (OP) with open and endovascular
procedures and aneurysm growth rate and risk of rupture in patients
managed nonoperatively (NOP). Secondary outcomes included renal artery
patency and need for reintervention in the OP group and kidney function in
the OP and NOP groups.
Results: There were 49 OP patients (34 females) and 66 NOP (31
females). Three RAAs ruptured (sizes: 34, 36, and 41 mm). Mean aneurysm
size was 26.8 6 8.9 mm (OP) and 13.6 6 5.2 mm (NOP; P < .001). A
total of 57% of patients in OP were symptomatic, with ﬂank pain (24%), he-
maturia (18%), and severe hypertension (18%). Nine (19%) and 29 (60%) of
OP patients had a RAA <20 and <30 mm, respectively. RAA location in the
OP included the primary bifurcation in 28, main renal artery in 8, upper and
lower segmental pole branches in 5 each, and middle segmental pole branch
in 2. Operative management included RAA resection and saphenous vein
graft (SVG) in 15, vein patch in 11, primary repair in 7, ex vivo reconstruc-
tion in 7, Dacron graft in 2, internal iliac artery patch in 1, and endovascularcoil embolization in 3. Mean renal ischemia time was 56 6 48 minutes (ex
vivo: 151 6 27 minutes; not ex vivo: 40 6 27 minutes). The 30-day mor-
tality was 0%. One patient had a nephrectomy at the time of repair due to
venous injury, and a second one occurred at 3.7 months due to SVG occlu-
sion. One patient underwent concomitant splenectomy. One patient’s oper-
ation was aborted due inﬂammation from a previously ruptured and coiled
RAA, who subsequently underwent deﬁnitive embolization. Complications
included pancreatitis (n ¼ 1) and reexploration for small bowel obstruction
(n ¼ 1) and bleeding (n ¼ 1). RAA reintervention was 0%. NOP RAAs were
followed up for 76.8 6 54.4 months and had a growth rate of 0.3 6 0.9
mm/y. There were no ruptures and no conversions to OP. Kidney function
in NOP remained stable (D glomerular ﬁltration rate, 5.4 6 21.1 mL/min)
but worsened in OP (D glomerular ﬁltration rate, 5.9 6 23.5 mL/min;
P ¼ .008).
Conclusions: No RAA <34 mm ruptured. Because the rate of
growth is slow and kidney function remains stable without repair, RAA
<30 mm should be observed unless symptoms occur.
Author Disclosures: Y. Erben: None; A. Duncan: None; A. Rizvi: None;
H. Bjarnason: None; M. Kalra: None; G. Oderich: None; M. Fleming:
None; R. De Martino: None; T. Bower: None; P. Gloviczki: None.
A Comparison of Results With Eversion Versus Conventional Carotid
Endarterectomy From the Vascular Quality Initiative
Joseph R. Schneider, MD,1 Andrew W. Hoel, MD,2 Irene B.
Helenowski, PhD,3 Cheryl R. Jackson, RN,4 Michael J. Verta, MD,4
Sung Ham, MD,5 Scott E. Musicant, MD,6 Nilesh H. Patel, MD,4
Stanley Kim, MD4. 1Surgery, Vascular and Interventional Program of
Cadence Health, Winﬁeld, Ill; 2Division of Vascular Surgery,
Northwestern, Chicago, Ill; 3Northwestern University School of
Medicine, Chicago, Ill; 4Vascular and Interventional Program of Cadence
Health, Winﬁeld, Ill; 5University of Southern California, Los Angeles,
Calif; 6Vascular Associates of San Diego, San Diego, Calif
Objectives: Carotid endarterectomy (CEA) is usually performed with
eversion (ECEA) or conventional (CCEA) techniques. Previous studies
report conﬂicting results with respect to outcomes for ECEA and CCEA.
We compared patient characteristics and outcomes for ECEA and CCEA.
Methods: Deidentiﬁed data for CEA patients were obtained from the
Society for Vascular Surgery Vascular Quality Initiative database. Patients
undergoing reoperative CEA or CEA concurrent with cardiac surgery
were excluded, leaving 2828 ECEA and 20,831 CCEA for comparison.
Univariate analysis compared patients, procedures, and outcomes. Survival
analysis was also performed for primary outcomes of mortality, cerebral
ischemic events, restenosis, and reintervention.
Results: Groups were similar with respect to gender, comorbidities,
and preoperative neurologic symptoms, except that ECEA patients tended
to be older (71.3 vs 69.9 years; P < .0001). CCEA was more often per-
formed with general anesthesia (92% vs 81%; P < .001) and with a shunt
(59% vs 24%; P < .001). Perioperative ipsilateral neurologic events (ECEA,
1.3% vs CCEA, 1.2%; P ¼ .90) and any stroke (1.0% vs 0.8%; P ¼ .38)
were uncommon in both groups. ECEA tended to take less time (100 vs
113 minutes; P < .001) but more often required a return to the operating
room for bleeding (1.4% vs 0.8%; P ¼ .003). Kaplan-Meier 30 day freedom
from stroke or death was similar (97.7% vs 97.6%; P ¼ .17). The 1-year
freedom from recurrent stenosis >50% was lower for ECEA (88.9% vs
94.1%; P < .0001). However, ECEA and CCEA both had a very high rate
of freedom from reoperation at 1 year (99.6% vs 99.5%; P ¼ .98).
Conclusions: ECEA and CCEA appear to provide similar freedom
from neurologic morbidity, death, and reintervention. ECEA was associated
with signiﬁcantly shorter procedure times. Furthermore, ECEA obviates the
expenses of a patch, typically used in CCEA, and a shunt, more often used in
CCEA in this database. However, these potential beneﬁts may be reduced
by a slightly greater requirement for early return to the operating room
for bleeding.
Author Disclosures: J. R. Schneider: None; A. W. Hoel: None; I. B.
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Cost Analysis of Trellis Device Versus Catheter-Directed Thrombolysis
for Lower Extremity Deep Vein Thrombosis
Jacob H. Rinker, MD, Douglas Massop, MD, Hayden L. Smith, PhD, Piper
Wall, DVM. UnityPoint Health e Des Moines, Surgical Residency
Program, Des Moines, Iowa
Objectives: This study assessed total costs for lower extremity
deep vein thrombosis (DVT) treatment using the Trellis device or
